Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

The CEO of Shield, Anders Lundstrom, stated that this partnership is in line with the company’s strategy to expand ACCRUFeR®’s global reach, emphasizing the significance of the Japanese ...

Commercial stage pharmaceutical firm Shield Therapeutics, which has a base in Gateshead, has entered into an exclusive licence agreement to commercialise its oral iron therapy drug in Japan. ITAL-NET ...

(Sharecast News) - Pharmacitucal firm Shield Therapeutics said on Tuesday that it had inked an exclusive licence agreement for its ACCRUFeR iron deficiency asset in Japan with VITAL-NET.

North East pharmaceutical firm Shield Therapeutics has signed a deal which will see it break into Japan - the third biggest market in the world. The Gateshead commercial stage drug business, which ...

Shares in Shield Therapeutics (LON:STXS) PLC (AIM:STX, OTCQX:SHIEF) rose as much as 6% on Tuesday morning after the company announced a licensing agreement that will see its iron deficiency treatment ...

The undersigned Japan-based organizations are writing to call on the Japanese government to protect the International ...

Did you know with a Digital Subscription to Shields Gazette ... “I think that it's going to be an absolute riot. There is a lot in this that they will not have seen before.

analyst at Japanese investment bank Daiwa. That factory handles a significant portion of Intel's chip production.

The Senators will be facing elimination on home ice Saturday when they host the Maple Leafs in Game 4 and head coach Travis Green wants his team to take it one game at a time. Tim Stützle says ...